Also, promising results achieved from the treatment of human U87 glioma-bearing mice models with IFN-β-secreting MSCs signified that MSCs could be recruited into the brain tissue after systemic or local delivery, thereby enabling human glioma treatment (Nakamizo et al., 2005). This evidence concerns the gene IFNB1 and central nervous system cancer.